Clinical Trials

Our physicians at Retina Specialists are nationally recognized and actively involved in multi-centered clinical trials on novel therapeutic approaches to vitreoretinal diseases. Our research team is committed to carefully selecting well-designed, safe clinical studies that offer promising and exciting new treatments for our patients. Our clinical trials are a valuable opportunity for patients to access novel treatments for Vitreoretinal diseases.

For more information or to refer a patient for evaluation, please contact our Clinical Trials Coordinator: Debbie Bolling at 972-599-9098 or dbolling@retinaspecialists.net

We participate in numerous active national eye research studies, including:

 

 Diabetic Retinopathy:

  • KESTREL (Protocol CRTH258B2301): Study of Efficacy and Safety of Brolucizumab v Aflibercept in Patients with Visual Impairment Due to Diabetic Macular Edema
    • Clinical Trials.Gov Identifier: NCT03481634
    • Principal Investigator: Santosh Patel, MD
    • Sponsor: Novartis Pharmaceuticals
    • Study Coordinator: Debbie Bolling (dbolling@retinaspecialists.com)
    • Status: Not Yet Recruiting or Enrolling

 

Retinal Vein Occlusion:

 TOPAZ (CLS1003-302): Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects with Macular Edema Following RVO

  • Clinical Trials.Gov Identifier: NCT03203447

o   Principal Investigator: Henry Choi, MD

 

Age-Related Macular Degeneration:

  • HAWK STUDY EXTENSION (CRTH258A2301-E1): Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
    • Clinical Trials.Gov Identifier: NCT03386474

o   Principal Investigator: Santosh C. Patel, MD

For more information or to refer a patient for evaluation, please contact our Clinical Trials Coordinator:

Debbie Bolling

972-599-9098
dbolling@retinaspecialists.net